Association of fluconazole pharmacodynamics with mortality in patients with candidemia.
作者信息
Arendrup Maiken C, Cuenca-Estrella Manuel, Donnelly J Peter, Lass-Flörl Cornelia, Rodriguez-Tudela Juan L
出版信息
Antimicrob Agents Chemother. 2009 Jun;53(6):2704-5; author reply 2705-6. doi: 10.1128/AAC.01411-08.
Abstract
摘要
相似文献
1
Association of fluconazole pharmacodynamics with mortality in patients with candidemia.氟康唑药效学与念珠菌血症患者死亡率的关联。
Antimicrob Agents Chemother. 2009 Jun;53(6):2704-5; author reply 2705-6. doi: 10.1128/AAC.01411-08.
2
Association of fluconazole pharmacodynamics with mortality in patients with candidemia.氟康唑药效学与念珠菌血症患者死亡率的关联。
Antimicrob Agents Chemother. 2008 Sep;52(9):3022-8. doi: 10.1128/AAC.00116-08. Epub 2008 Jun 30.
3
Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.通过流式细胞术进行氟康唑的抗真菌药敏试验与临床结果相关。
J Clin Microbiol. 2001 Jul;39(7):2458-62. doi: 10.1128/JCM.39.7.2458-2462.2001.
4
EUCAST technical note on fluconazole.欧洲临床微生物与感染病学会（EUCAST）关于氟康唑的技术说明。
Clin Microbiol Infect. 2008 Feb;14(2):193-5. doi: 10.1111/j.1469-0691.2007.01899.x. Epub 2007 Dec 5.
5
In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.突破性念珠菌血流分离株的体外药敏性与氟康唑的每日剂量和累积剂量相关。
Antimicrob Agents Chemother. 2006 Oct;50(10):3496-8. doi: 10.1128/AAC.00741-06.
6
Attributable mortality of nosocomial candidemia, revisited.医院念珠菌血症的归因死亡率，再探讨。
Clin Infect Dis. 2003 Nov 1;37(9):1172-7. doi: 10.1086/378745. Epub 2003 Oct 8.
7
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.氟康唑实时药敏试验在念珠菌血症治疗中的应用价值。
Diagn Microbiol Infect Dis. 2004 Oct;50(2):119-24. doi: 10.1016/j.diagmicrobio.2004.06.004.
8
Risk factors for candidemia-related mortality at a medical center in central Taiwan.台湾中部某医学中心念珠菌血症相关死亡率的危险因素。
J Microbiol Immunol Infect. 2006 Apr;39(2):155-61.
9
Frequency and clinical significance of bloodstream infections caused by C albicans strains with reduced susceptibility to fluconazole.
Diagn Microbiol Infect Dis. 2002 Oct;44(2):163-7. doi: 10.1016/s0732-8893(02)00432-7.
10
Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro.由体外对氟康唑敏感的白色念珠菌和近平滑念珠菌引起的新生儿及婴儿突破性真菌血症。
J Antimicrob Chemother. 2001 Oct;48(4):521-5. doi: 10.1093/jac/48.4.521.
引用本文的文献
1
In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.体内微透析法测定脓毒症重症监护病房患者皮下组织间液中氟康唑的渗透情况及药代动力学
Antimicrob Agents Chemother. 2015 Nov 23;60(2):827-32. doi: 10.1128/AAC.02461-15. Print 2016 Feb.
2
Characteristics of hospital-acquired and community-onset blood stream infections, South-East Austria.奥地利东南部医院获得性和社区获得性血流感染的特征
PLoS One. 2014 Aug 8;9(8):e104702. doi: 10.1371/journal.pone.0104702. eCollection 2014.
3
Epidemiology and antifungal resistance in invasive candidiasis.侵袭性念珠菌病的流行病学和抗真菌耐药性。
Eur J Med Res. 2011 Apr 28;16(4):187-95. doi: 10.1186/2047-783x-16-4-187.
本文引用的文献
1
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.当按照CLSI M27-A2标准方法检测念珠菌属时，在24小时而非48小时读取氟康唑最低抑菌浓度（MIC）的理论依据。
Antimicrob Agents Chemother. 2008 Nov;52(11):4175-7. doi: 10.1128/AAC.00420-08. Epub 2008 Sep 22.
2
Association of fluconazole pharmacodynamics with mortality in patients with candidemia.氟康唑药效学与念珠菌血症患者死亡率的关联。
Antimicrob Agents Chemother. 2008 Sep;52(9):3022-8. doi: 10.1128/AAC.00116-08. Epub 2008 Jun 30.
3
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.氟康唑的最低抑菌浓度（MIC）及剂量/MIC比值与黏膜念珠菌病和念珠菌血症患者治疗反应的相关性。
Antimicrob Agents Chemother. 2007 Oct;51(10):3599-604. doi: 10.1128/AAC.00296-07. Epub 2007 Jul 23.
4
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.非中性粒细胞减少的念珠菌血症患者中氟康唑浓度-时间曲线下面积/MIC及剂量/MIC比值与死亡率的相关性
Antimicrob Agents Chemother. 2007 Jan;51(1):35-9. doi: 10.1128/AAC.00474-06. Epub 2006 Nov 13.
5
Pharmacokinetics and pharmacodynamics of antifungals.抗真菌药物的药代动力学和药效学
Infect Dis Clin North Am. 2006 Sep;20(3):679-97. doi: 10.1016/j.idc.2006.06.007.
6
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.氟康唑的最低抑菌浓度（MIC）以及氟康唑剂量与MIC的比值与念珠菌血症患者的治疗反应相关。
Antimicrob Agents Chemother. 2005 Aug;49(8):3171-7. doi: 10.1128/AAC.49.8.3171-3177.2005.
7
In vivo pathogenicity of eight medically relevant Candida species in an animal model.八种医学相关念珠菌在动物模型中的体内致病性
Infection. 2002 Oct;30(5):286-91. doi: 10.1007/s15010-002-2131-0.
8
Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.接受氟康唑治疗的非艾滋病重症念珠菌感染患者抗真菌大稀释度药敏试验结果的临床相关性
Antimicrob Agents Chemother. 2000 Oct;44(10):2715-8. doi: 10.1128/AAC.44.10.2715-2718.2000.
9
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.在中性粒细胞减少小鼠播散性念珠菌病感染模型中氟康唑药效学的表征与定量分析
Antimicrob Agents Chemother. 1999 Sep;43(9):2116-20. doi: 10.1128/AAC.43.9.2116.
10
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.氟康唑在系统性念珠菌病小鼠模型中的药效学
Antimicrob Agents Chemother. 1998 May;42(5):1105-9. doi: 10.1128/AAC.42.5.1105.
Zotero 插件